Review
This article reviews an updated therapeutic algorithm for heart failure with reduced ejection fraction (HFrEF) with a special focus on the therapeutic value of adding an mineralocorticoid receptor antagonist, changing an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for an angiotensin
II receptor-neprilysin inhibitor and incorporating an sodium–glucose cotransporter 2 inhibitor in patients with HFrEF.
Review
This article provides an overview of the main pathophysiological characteristics of heart failure with preserved ejection fraction (HFpEF), the considered diverse biological effects of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in this context and the supporting clinical evidence of SGLT2i in patients with HFpEF with a focus on the EMPEROR-Preserved and DELIVER trials.
Original Research
This study evaluates dapagliflozin in
patients with type 2 diabetes in clinical practice in Spain.
Review
This review describes the results of the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) trial and the recently published Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction (DEFINE-HF) trial. In addition, the thought-to-be mechanisms of action of SGLT2 inhibitors beyond their known glucose-lowering effects.
Review
Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets. New agents that reduce blood glucose concentrations by novel mechanisms and have acceptable safety profiles are needed to improve glycemic control and reduce complications. This article reviews the evidence from clinical trials and suggests that SGLT2 inhibitors are a promising new treatment option for T2DM.
